EGX-listed Rameda Pharma has acquired an new anticoagulant molecule, the company said in a press release this morning (pdf). The company didn’t name the molecule, but said the acquisition was part of its strategy to grow its portfolio by buying drugs with “an established market presence.” The company said the acquisition will be its largest to date and will see the company “benefit from a large and fast-growing therapeutic area that has displayed a 3-year CAGR of c.67% between 2017 and 2020.”

FACT CHECK- Azimut has not yet committed to starting an FX fund, but is simply mulling the idea, Azimut MD Ahmed Abo El Saad tells us, refuting a story that broke yesterday in the local press.

Dana Gas is, for once, happy with our arrears payments, reporting in a release (pdf) that 1H2021 collections from Kurdistan and Egypt have increased 106% y-o-y to USD 185 mn — the highest level in more than five years. Dana, which routinely complains loudly about the pace at which Egypt pays it, was reported in April to be in arbitration with IPR Wastani after Dana reneged on an agreement to sell most of its on-shore Egypt assets in a USD 236 mn transaction.